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We estimate that 208,000 deep brain stimulation (DBS) devices have been implanted
to address neurological and neuropsychiatric disorders worldwide. DBS Think Tank
presenters pooled data and determined that DBS expanded in its scope and has been
applied to multiple brain disorders in an effort to modulate neural circuitry. The DBS Think
Tank was founded in 2012 providing a space where clinicians, engineers, researchers
from industry and academia discuss current and emerging DBS technologies and
logistical and ethical issues facing the field. The emphasis is on cutting edge research
and collaboration aimed to advance the DBS field. The Eighth Annual DBS Think Tank
was held virtually on September 1 and 2, 2020 (Zoom Video Communications) due
to restrictions related to the COVID-19 pandemic. The meeting focused on advances
in: (1) optogenetics as a tool for comprehending neurobiology of diseases and on
optogenetically-inspired DBS, (2) cutting edge of emerging DBS technologies, (3) ethical
issues affecting DBS research and access to care, (4) neuromodulatory approaches
for depression, (5) advancing novel hardware, software and imaging methodologies,
(6) use of neurophysiological signals in adaptive neurostimulation, and (7) use of more
advanced technologies to improve DBS clinical outcomes. There were 178 attendees
who participated in a DBS Think Tank survey, which revealed the expansion of DBS
into several indications such as obesity, post-traumatic stress disorder, addiction and
Alzheimer’s disease. This proceedings summarizes the advances discussed at the
Eighth Annual DBS Think Tank.
Keywords: DBS (deep brain stimulation), neuroethics, optogenetics, novel hardware, adaptive DBS, neuroimaging
INTRODUCTION
The Eighth Annual deep brain stimulation (DBS) Think
Tank meeting was held virtually on September 1 and 2,
2020 (Zoom Video Communications) due to restrictions
related to the COVID-19 pandemic. The DBS Think Tank
presenters pooled data and determined that DBS has
expanded in its scope and has been applied to multiple
brain disorders. There have now been an estimated 208,000
DBS devices implanted for neurological and neuropsychiatric
disorders worldwide. The DBS Think Tank was founded
in 2012 and provides a space where clinicians, engineers,
clinical-researchers, basic researchers and scientists from
both industry and academia engage in discussions on
current and emerging DBS technologies as well as tackle
logistical and ethical issues facing the field. The DBS
Think Tank has an emphasis on cutting edge research and
collaboration which is aimed to more rapidly advance the
DBS field.
The DBS Think Tank meeting was focused on advances in the
following areas:
(1) optogenetics as a tool for comprehending the neurobiology
of diseases and on optogenetically inspired DBS,
(2) the cutting edge of emerging DBS technologies,
(3) ethical issues affecting DBS research and access to care,
(4) neuromodulatory approaches for depression,
(5) advancing novel hardware, software and imaging
methodologies,
(6) the use of neurophysiological signals in adaptive
neurostimulation,
(7) the use of more advanced technologies to improve DBS
clinical outcomes,
(8) the use of novel techniques such as INTRSECT (intronic
recombinase sites enabling combinatorial targeting),
(9) an updated survey of 178 attendees which is performed
each year to track trends in the field.
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These proceedings will summarize the Eighth Annual DBS
Think Tank meeting.
OPTOGENTICALLY-INSPIRED DBS
Optogenetics has advanced our comprehension of the
pathophysiology and neurobiology of disease, and continues
to bring promise to our fundamental comprehension of the
role of specific cell types, and even single cells, in the brain.
Channelrhodopsins are naturally occurring light-gated ion
channels in algae, which have become important in neuroscience
research for targeted control of specific circuit elements with
optogenetic techniques. Here we discuss how optogenetics as
a research tool can be used to uncover underlying circuitry
and to motivate new approaches for applying DBS into the
human population.
Inner Workings of Channelrhodopsins
It was Francis Crick who first suggested the rather far-fetched
idea that light could be a useful tool for the investigation
of neural function and that it could be used in a targeted
manner. Since then, converging advances in genetics, optics and
engineering have collectively shown substantial promise for the
investigation of neurological diseases. Current neuromodulation
methods (achieved via DBS) tend to stimulate all neurons in a
certain volume of tissue, which may include cells not involved
in disease and thus likely result in undesirable side-effects.
Hence, controlling the activity of specific neurons has significant
potential to advance the field of neuromodulation. Cell specific
excitation (or inhibition) of neurons can be achieved using
light via microbial opsins, which encode all-in-one proteins
including ion channels called channelrhodopsins that transduce
photons into electrical current (Nagel et al., 2002; Deisseroth
and Hegemann, 2017), enabling the first temporally precise
control of genetically targeted cells in behaving mammals
(Adamantidis et al., 2007). One of the early studies showing
the generality of this methodology in an exploration of the
role of bed nucleus of the stria terminalis (BNST) circuit
elements in modulating anxiety, involved integrating behavior,
electrophysiology, respiratory physiology, and optogenetics.
It was discovered that three BNST efferent projections—to
the lateral hypothalamus, parabrachial nucleus, and ventral
tegmental area—each corresponded to a unique aspect of
anxiolysis: that is, reduced risk-avoidance, reduced respiratory
rate, and positive valence of the state, respectively (Kim et al.,
2013). Subsequent studies revealed that optogenetics recruits
naturalistic patterns of downstream neuronal population activity
(Allen et al., 2019; Jennings et al., 2019). One of these studies
(Allen et al., 2019) utilized optogenetics to recruit neurons that
were normally activated upon deprivation of water, by providing
input to the median preoptic nucleus of the hypothalamus
(MnPO), while simultaneously recording from thousands of
neurons across the brain using electrophysiology; all during
behavior. It was found that targeted optogenetics recruits a
naturalistic brain-wide pattern of activity like that elicited by
natural thirst and water-seeking behavior (Allen et al., 2019).
Recruitment of opsins to modulate neuronal circuitry at
the single cell level in living mammals was initially achieved
via two photon activation of neurons (Prakash et al., 2012).
This ultimately enabled the first specified-single-cell control
of mammalian behavior, via interrogation of orbitofrontal
(OFC) neurons during distinct and different behaviors: feeding
responses and social interaction (Jennings et al., 2019). Feeding
responsive OFC neurons were selected for optogenetic control;
it was found that specific modulation of these cells was able
to enhance feeding behavior. In order to determine if these
behavioral effects associated with stimulation were specific to
the feeding cells, OFC cells not involved in feeding behavior
(social behavior-responsive cells) were stimulated, and found to
instead result in inhibition of feeding. These experiments inform
on the role of well-defined OFC networks involved in feeding
and social behaviors and demonstrate that mammalian behavior
can be specifically controlled via modulation of individual
cells within a network, and that optogenetic identification of
subnetworks results in elucidation of the dynamics involved in
primary motivational drives. The discovery of ChRmine, a fast
and highly sensitive red-shifted opsin, has recently facilitated
precise control over large ensembles of individually specified
single cells in behavior (Marshel et al., 2019), and is suitable
for deep transcranial optogenetic modulation of behavior in
mouse, as was seen in a later paper addressing multiple specific
behaviors including appetitive conditioning (Chen R. et al.,
2020). This methodology makes it possible for the exploration
of therapeutic interventions wherein the source of light can be
distinctly separated from the target cell population. Thus, specific
adaptive behavior can be elicited via deep transcranial ChRmine
photoactivation, which precludes the need for intracranial
surgery. In parallel with the revolution arising from optogenetic
approaches, the recent explosion of single-cell transcriptomic
data has made clear that cell types can be usefully targeted by
more than one genetic feature. INTRSECT (intronic recombinase
sites enabling combinatorial targeting) addresses this opportunity
by allowing the expression of adeno associated virus (AAV) based
payloads by combining synthetic introns, and two recombinases
(Cre and Flp) defining cellular populations specified by two
features. INTRSECT has been used to identify functional roles
for projection patterns of diverse neuronal subtypes (Chuhma
et al., 2018; Poulin et al., 2018; Fenno et al., 2020) in physiology
and behavior. Further development of this approach has resulted
in a triple recombinase dependent gene targeting approach
(Triplesect) (Fenno et al., 2020); this technology can achieve
superior viral targeting specificity and will likely result in the





Over the past years, chronically sensed brain signals have been
established as an important new opportunity for advancing
the standard of care (SOC) in DBS therapies. Historically,
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access to such signals has been available on a limited basis via
investigational devices specialized for such recordings, which
have collectively allowed constrained exploration of such signals
in research contexts. However, these signals were the impetus
of significant scientific and technological discoveries in the
DBS space. In the research literature, it has been shown that
such signals are robust and chronically present over months
to years (Abosch et al., 2012; Giannicola et al., 2012; Trager
et al., 2016; Neumann et al., 2017), that they often correlate
with patient symptoms and additionally can be used with the
delivery of therapy (both stimulation and medications) (Kuhn
et al., 2006; Quinn et al., 2015; Trager et al., 2016; Neumann
et al., 2017), and finally that it is feasible and there may
be benefits to applying closed-loop methodologies using these
correlations to adapt therapy over time and thereby adjust for
fluctuations in symptoms (Velisar et al., 2019; Petrucci et al.,
2020). With the first availability of commercial devices (Percept
PCTM) to implement chronically sensed brain signals, these
opportunities for clinical value have become available more
broadly. Very early evidence (Koeglsperger et al., 2020) suggests
that the findings of the research community can be replicated
in these commercial devices, demonstrating the feasibility of
using in-clinic signals during the programming process and at-
home signals to understand the real-world characteristics of
signals outside the clinic. The next opportunity to be explored
is chronic closed-loop or adaptive therapies in naturalistic
settings. Medtronic’s Percept PCTM is enabled for these types
of control algorithms through a software unlock, and these
capabilities will be explored via industry-sponsored studies in
Parkinson’s disease (PD; e.g., ADAPT PD – NCT04547712)
beginning early in 2021. The Percept PCTM platform has also
been architected to unlock other advanced capabilities with
appropriate regulatory approvals for research, including novel
stimulation waveforms, network connectivity, and directional
sensing with DBS leads bearing segmented electrodes. Research-
enabled commercial device platforms such as the Percept PCTM
are poised to enable more rapid research translation through
faster access to technological innovations and also offer fewer
tradeoffs to clinical researchers and to research subjects.
Advancement of DBS device technology has made it possible
to have multiple combinations of DBS programming settings in
an effort to deliver better outcomes. Device programming on the
other hand has only become more complicated. The development
of a computer-guided closed-loop based programming algorithm
could potentially make DBS programming easier for clinicians.
In this context, Boston Scientific Neuromodulation (BSN) is
working to improve tools to aid the clinical DBS workflow.
These tools broadly include computer-aided programming (using
objective outcome measurements), as well as stimulation field
modeling with specificity to patient anatomy, which has been
pursued through Boston Scientific’s CLOVER Study. CLOVER
(NCT03037398) is a multi-center study which uses direct
and objective symptom measures, such as from PD-validated,
commercial finger-worn accelerometers, and integrates these
measurements with a BSN-developed search and optimization
algorithm. After three starting measurements, this algorithm
iteratively suggests the next settings to test, until an optimum
setting is found. Such an algorithm could assist both in-clinic
and in remote programmers. BSN has recently updated the
CLOVER algorithm to support programming of their directional
leads. The preliminary results indicate that the new algorithm
is able to converge in a single visit on stimulation settings that
result in UPDRS motor score reductions (as compared to the
baseline scores) that are statistically equivalent to multi-visit
SOC programming (as defined by the clinician in the study)
(Sasaki et al., 2021).
Programming may also be aided using patient imaging data
paired with three-dimensional stimulation models in the Guide
XT software, developed in collaboration with BrainLab. When
available, the combination of surgical, imaging, and stimulation
response (such as aggregated therapy sweet spots) with real-
time clinical response may further assist DBS programmers. BSN
is working toward tools to enable large scale, group studies
to further investigate the relationships between stimulation
locations and clinical outcomes, including using population
statistics in order to build probabilistic maps of stimulation.
The results of these population-based analyses could be used
to inform programming software. More research is needed to
further explore the predictive value of these maps and their
potential use in routine clinical DBS programming practices.
Real-world analyses of claims data have previously shown a
higher rate of DBS revision/removal procedures than typically
recognized (Rolston et al., 2016). The impact of modern systems,
with significant advancements in design and manufacturing,
has not been previously studied. Abbott labs presented a study
evaluating the impact of a modern DBS system on revision and
replacement rates. Medicare fee for service claims were used
to identify patients undergoing DBS implantation for PD or
Essential Tremor between January 1, 2016–December 31, 2018.
Claims records were linked to manufacturer device registration
data to identify which patients had been implanted with Abbott
Infinity, at the time the only commercially available system in
the United States with directional stimulation capability; linked
patients were assigned to the Treatment (Directional System)
group. A total of 3,271 patients in Omnidirectional and 596
patients in Directional System group met the inclusion/exclusion
criterion. Revision or replacement rates in patients implanted
with the Infinity directional DBS system were significantly
reduced compared to those with traditional omni-directional
DBS systems. Further analysis and future studies may elucidate
the mechanism of reduced risk. Another study evaluated
an investigational software extension that enabled remote
programming of previously implanted DBS devices. The paucity
of trained neurologists and urban concentration of specialty
care centers has contributed to care access burden for patients
with DBS and their caregivers, particularly in the context of
the COVID-19 pandemic. Remote monitoring1 and remote
support technologies2 have been established in other Class 3
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systems has been enabled by China-based manufacturers but is
not yet available in countries requiring CE or FDA approvals
(Zhang et al., 2018). Abbott investigated an investigational
remote programming feature to enable programmers to directly
adjust DBS therapy settings in real-time via a secure video-based
mobile platform in patients implanted with an InfinityTM DBS
system3. The primary endpoint of this study was to determine
remote programming safety by evaluating adverse events (AEs)
reported by subjects within three weeks of a programming session
which was conducted using the remote programming feature.
Ten subjects connected with their treating clinician through
the secure remote programming feature. No serious AEs were
reported in this study and anticipated, non-serious AEs that were
reported for 1 subject resolved without sequalae. Evaluation of
such remote programming features will likely advance the field
towards low-burden therapy options for patients and clinicians
in the rapidly emerging digital health realm.
ON TARGET, AND (YET) OFF-LABEL
USES OF DBS: ETHICAL CONCERNS,
CAVEATS, AND CONSIDERATIONS
With the increased investigation and subsequent use of novel
DBS therapies, there has been a simultaneous growth in ethical
issues and considerations. One important issue that has been
emerging is continued device access after the conclusion of a
research study, which is generally considered to be ethically
appropriate and desirable. Ascertaining whether researchers and
industry sponsors are ethically obligated to facilitate continued
access to those participants whose benefit requires a dialogue
and engagement of all the relevant stakeholders. Additionally,
the potential of DBS technologies for off-label use and the ethics
surrounding this, specifically in vulnerable patient populations,
must also be developed and subsequently reviewed.
DBS for Less Prevalent Diseases,
Continued Access After Trials and the
NIH BRAIN Initiative Ethics Updates
The use of various forms of neurotechnologies and techniques
to define and model loci for possible interventional
neuromodulation is opening new vistas of “on target,” and
(yet still) off-label uses of DBS (Ramirez-Zamora et al., 2017,
2019) see, for example, this report. As we have noted, such
new horizons of possibility must be approached with ethical
probity (Giordano, 2015). The novelty of utilizing DBS in such
ways mandates explication of current uncertainties about the
durability of clinical benefit, future side effects, and sustainability
of intervention as contingencies for informed patient consent
(Giordano, 2016).
That DBS affords effective clinical benefit can be seen as
only an initial component (and hurdle) of successful care.
Indeed, there have been—and remain—ethical and policy
3https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=
12619001660178
challenges regarding post-trial management of brain implant
devices (Lazaro-Munoz et al., 2018; Sierra-Mercado et al., 2019).
Brain implant trials generally do not have provisions to ensure
that patients/subjects who gain clinical benefit from the use
of DBS will have access to maintenance of the device after
completion of the trials.
Patients who participate in these trials have severe and
treatment-resistant neuropsychiatric conditions. Axiomatically,
patients with “treatment-resistant” disorders who benefit from
an experimental DBS intervention during a trial have no other
effective treatment alternatives; and guaranteed provision of
services and resources to assure maintenance of DBS devices
upon completion of such trials is lacking. To be sure, such
continued maintenance may incur significant costs. While
sustainability of these devices for extant (CPT-code listed)
indications may be covered by health insurance providers, such
coverage is not obligated (and therefore is routinely not provided)
for those indications that are experimental (Rossi et al., 2017).
The significant burdens (i.e., surgery, multiple clinical visits)
incurred by participants in these trials heighten their dependence
upon the study teams for access to the only intervention that
has afforded them successful clinical outcomes. Thus, we posit
that these patients’ vulnerability is increased, and in this light,
strongly advocate development of a system to ensure (and insure)
post-trial continuity of clinical care for those patients/subjects
for whom therapeutic benefits are achieved. Public and private
research sponsors, device manufacturers, researchers—and the
institutions in which this research occurs—can, and we believe
should, play active roles in facilitating both the discourse as
well as the resources required to assure these patients’ continued
access to successful clinical care.
Of additional interest, particularly for experimental (i.e., off-
label) uses of DBS are potential side effects that can occur
in either the short, intermediate, or long-term. Provocative
questions have arisen whether closed-loop neuromodulation
could induce changes to a patients’ sense of identity and agency.
Ongoing discussions in the literature have been equivocal,
noting a paucity of data and arguing that such concerns
may be overdrawn (Giordano, 2016). To address the need for
empirical investigations, we at UCSF examined constructs and
the subjective experience of identity in patients with refractory
epilepsy undergoing responsive neurostimulation (RNS)—the
first FDA-approved, commercially available closed-loop brain
stimulation system. Pre- and post-implantation observations of
12 patients were conducted, in addition to in-depth interviews
with both these patients and their respective caregivers. These
interviews revealed that patients and caregivers did not attribute
any perceived changes in patients’ identity or agency to the
device’s operation, thereby refuting concerns that have been
raised in the (conceptual) neuroethics literature. When such
changes were noted, they were readily and characteristically
described by patients and caregivers as attributable to their
disorder, or as side effects of medications. Importantly, these
reports indicated that the qualitative techniques used were able
to elicit such concerns if and when present.
An unexpected finding was that the ability to view the
neural recordings collected by the device was regarded as highly
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meaningful and personally significant to patients and caregivers;
in some cases, independent of the device’s stimulation algorithm
and/or effect(s). Notably, patients reported that neural recordings
enabled visual demonstration of the disease process in ways that
affected their understanding of the disorder, and themselves.
These are the first such empirically obtained findings from
clinical populations undergoing closed-loop neuromodulation,
which we believe illustrate—and support—how empirical studies
can and should inform the conceptual neuroethics literature.
DEPRESSION DBS: WHERE CAN WE
GO? LESS VS MORE FOR DBS
DEPRESSION
Major depressive disorder (MDD) is a prevalent disease, and
one of the leading causes of disability worldwide (Giacobbe
et al., 2009). A failure to identify and treat depression can have
profound negative public health impacts such as hospitalizations,
inter-personal issues, lack of productivity, and suicide. After
early randomized controlled trials failed to show improvement,
it is now becoming increasingly evident that DBS can be
useful for treatment resistant depression, and several studies are
showing promise (Holtzheimer et al., 2017; Hitti et al., 2020;
van der Wal et al., 2020) Bergfeld, 2020). Stimulation of the
subgenual cingulate has been shown to produce clinical benefits
in patients with treatment resistant depression (Mayberg et al.,
2005). Increased clinical benefits in these trials has stemmed
from improvements in neuroimaging, personalized targeting,
neurophysiology and stimulation delivery. Neuroimaging has
aided in personalized lead targeting by defining critical white
matter tracts that may be crucial in the pathology of depression.
Furthermore, sites (discussed herein) have been using a network-
based approach adopted from epilepsy which entails the
temporary implantation of stereo-EEG electrodes either to
study the network involved in depression, to choose optimal
stimulation settings, or to demonstrate biomarkers that can be
used in a closed-loop paradigm. As these neurophysiologic data
are collected in both the temporary and long-term settings using
devices such as the Summit RC+ S, the heterogeneity in response
to DBS may be elucidated and more refined symptom-specific
biomarkers may be discovered. These advances will ultimately
produce optimized DBS paradigms which are specific to each
patient’s symptoms. Here we describe advances made in the field
of DBS for depression across three different centers.
Baylor Preliminary Experience
Depression DBS Trial
Deep brain stimulation for severe, treatment-resistant depression
(TRD) is an investigational therapy. Previous studies have
shown heterogeneous results, with early open-label studies
demonstrating promise (Holtzheimer et al., 2012); however,
industry-sponsored, blinded randomized trials were stopped
at interim analyses points without demonstrating a difference
between active and sham stimulation (Holtzheimer et al., 2012).
We propose that an important limitation in applying DBS
for this indication has been an incomplete understanding of
the network of brain regions responsible for the multifactorial
dysfunction underlying depression. To address this limitation,
we applied an approach borrowed from another challenging and
highly individualized disorder: epilepsy. As is done commonly
in epilepsy, our study involves intracranial recordings using
temporarily placed stereo-EEG (sEEG) electrodes in brain
regions hypothesized to be within the TRD networks. We
simultaneously place permanent DBS leads in two bilateral
regions: the ventral capsule/ventral striatum (VCVS) and sub-
callosal cingulate (SCC) regions (Figure 1). The patient is kept
in the hospital “neurophysiological monitoring unit” (NMU) for
10 days and undergoes a number of recording and stimulation
activities to understand brain network neurophysiology across
a variety of states (resting/baseline, emotional valence states,
cognitive effort states) and in response to stimulation across
a variety of stimulation parameters (frequency, pulse width,
amplitude, direction). One of the many goals of this intracranial
recording phase is to narrow the vast parameter space to a few
parameter sets that can be implemented in the chronic outpatient
phase of the trial.
We report the results from the first patient in this trial
(NCT03437928), which is funded by the NIH BRAIN Initiative
(UH3 NS103549; PIs Sheth, Pouratian, Goodman). This trial
was approved by the FDA (IDE G180300) and IRB. We
gathered a plethora of data during the intracranial phase that
helped to create a model of the relationship between imaging,
neurophysiology, and behavioral/symptomatic response. We
used this information to create three parameter sets, which we
tested in the outpatient phase. Implementing these individualized
parameter sets across the four DBS leads led to a steady reduction
in symptom scores, such that the subject achieved symptom
remission by 22 weeks.
We propose that “sEEG-guided DBS” is a useful platform
for developing a network understanding of disorders and that
this approach will provide sufficient information to optimize
neuromodulatory therapies such as DBS. Future challenges
include balancing the competing drives of optimizing previously
studied DBS targets versus exploring new targets, properly
interpreting acute results for chronic use, and translating this
paradigm so that in the future, inpatient intracranial recordings
will not be needed.
UCSF Preliminary Experience From an
Ongoing Depression Trial
MDD is a common and highly disabling disorder worldwide.
While the majority of patients respond well to medication
and psychotherapy, a substantial number of patients remain
refractory to all available treatments. DBS is a highly promising
therapy for this subset of patients with treatment resistant
disease. However, results from randomized controlled studies
of DBS for depression have not been consistent, suggesting
that novel strategies in DBS treatment are needed. Three
approaches toward DBS optimization in depression are currently
underway by groups at Mt. Sinai, Baylor and UCSF. They
include enhanced target engagement through tractography
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FIGURE 1 | Implant plan. StereoEEG electrodes (red) are placed in a variety of brain regions thought to be part of the depression network (dorsolateral prefrontal
cortex, dlPFC; ventrolateral PFC, vlPFC; dorsomedial PFC, dmPFC; medial and lateral orbitofrontal cortex, mOFC, lOFC; dorsal anterior cingulate cortex, dACC;
medial temporal lobe, MTL). DBS leads (blue) are placed in the subcallosal cingulate (SCC) and ventral capsule/ventral striatum (VC/VS). Placement is individualized
using tractography derived from diffusion MRI.
and biomarker development, DBS parameter optimization
through individualized network targeting, and development of a
personalized closed-loop paradigm.
At UCSF, we are conducting a 3-stage feasibility study of
personalized closed-loop stimulation for treatment resistant
MDD. Surgical implantation of 10 intracranial EEG electrodes
allows for personalized stimulation site selection and biomarker
discovery over 10 days of intensive in-patient monitoring.
Intracranial-EEG electrodes are then removed and a chronic
DBS device (NeuroPace RNS R© System) is implanted in sensing
and stimulation targets identified in the discovery stage. An
open label period follows where a biomarker-based detection
algorithm is developed and integrated into closed-loop therapy
and then tested through a randomized controlled study. In
this talk, we discuss the rationale behind a closed-loop DBS
approach. We discuss the conceptualization of depression in
a closed-loop model, implications for patient selection, and a
strategy for personalized clinical mapping that integrates clinical
responses with functional and structural connectivity mapping.
We highlight differences of our approach in comparison to the
approaches at Mt. Sinai and Baylor and suggest strategies for
integration of the three complementary efforts (Figure 2).
Optimizing SCC DBS for TRD Using
Chronic Sensing: Less Versus More
It has been 15 years since the first proof-of-principle report of
DBS for treatment resistant depression, targeting the subcallosal
cingulate (SCC) region (Mayberg et al., 2005). Initial studies
were catalyzed by critical clinical need, informed by converging
findings from imaging studies of depression pathophysiology and
antidepressant treatment, and operationalized using established
imaging standards for movement disorder surgery including
trial-and-error behavior testing during chronic stimulation at
individual contacts on each implanted DBS lead (Kennedy
et al., 2011; Holtzheimer et al., 2012). As SCC DBS has
evolved and matured, neuroimaging continues to play a
crucial role, with implementation of refined multimodal
techniques for surgical targeting and long-term studies of
treatment mechanisms (Crowell et al., 2019). Most critically,
increased precision has been achieved with implementation of
an individualized tractography-guided, template-matching lead
implantation procedure (Figure 3), now successfully deployed in
two successive cohorts, with a resulting 6- month response rate of
80% (8 of 11 patients) (Riva-Posse et al., 2018) and 90% (9 of 10
patients) (unpublished), respectively.
This standardized method for reproducible lead implantation
and contact selection for chronic stimulation has been further
verified by robust and reproducible intraoperative behavioral
effects associated with unilateral and bilateral therapeutic
stimulation at the predefined targets (Smart et al., 2018; Riva-
Posse et al., 2020). With this critical variable of reliable targeting
now achieved, current experiments have been focused on
outpatient strategies to characterize the unexplained differences
in the speed and trajectory of antidepressant effects facilitated
by chronic DBS. Such studies have been enabled by device
innovations, specifically the Activa PC + S and Summit RC + S
systems (Medtronic), that have facilitated ongoing interrogation
of DBS mechanisms at the neural level (Veerakumar et al.,
2019). To further refine and optimize DBS treatment, neural
biomarkers that reliably track the depression state over time
and that can discriminate depression relapse from transient
fluctuations in negative mood and from arousal are needed.
Ideally, these new brain tracking metrics would be derived using
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FIGURE 2 | Personalization in Targeting. Closed-loop DBS model for depression, patient selection, and personalized clinical mapping integrating clinical responses,
functional and structural connectivity mapping.
FIGURE 3 | Individualized tractography-guided, template-matching lead implantation procedure for SCC DBS for TRD. (A) 4-bundle tractography target template
(Riva-Posse et al., 2014). (B) Overlap of whole-brain deterministic tractography in patient-specific stereotactic frame space using the “StimVision” toolbox (Noecker
et al., 2018). (C) Initial placement of electrode within SCC and visualization of WM pathways passing through the VTA. (D) Personalized optimal electrode location
with the arc and ring angle determination by a neurosurgeon. Estimated VTA with standard stimulation settings (i.e., 3.5V, 130Hz, 90ms) is visualized with local field
potential recording from adjacent contacts (sandwiching recording to minimize stimulation artifact). Composite images courtesy of Ki Sueng Choi, Icahn School of
Medicine at Mount Sinai.
novel quantitative behavioral assessments that are not totally
dependent on patient self-report. While standardized depression
rating scales are generally effective in establishing the clinical
efficacy of DBS, they may be inadequate to develop neural control
policies in order to monitor and to optimize DBS delivery.
To this point, preliminary studies have demonstrated that
following 2 months of therapeutic SCC DBS, machine learning
models of facial expression and vocal inflection drawn from
unstructured patient interviews can reliably predict 6-month
outcomes, outperforming classical depression severity rating
scales (Harati et al., 2020). However, these methods have not yet
fully exploited the richness of the available recorded brain derived
datasets. Quantitative analyses of facial, voice, and body dynamics
combined with concurrent home and lab recordings of SCC LFPs
and self-paced video diaries have been undertaken (in progress)
to test this hypothesis, with the goal to further streamline and to
optimize SCC DBS for TRD.
NEW HARDWARE/SOFTWARE/IMAGING
Advances in MRI technology has made it feasible to visualize
brain networks in a manner previously thought to be impossible.
The Human Connectome Project has enabled the generation
of publicly available normative connectomes, which has proven
invaluable for neuromodulation research (Yeo et al., 2011;
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Van Essen et al., 2012; Holmes et al., 2015). Neuroimaging
improvements have enabled the identification of pathological
circuits responsible for symptom manifestations, thus potentially
leading to advances like personalized, connectivity-driven lead
targeting. Furthermore, neuroimaging can help aid in the
accurate mapping of the patient-specific stimulated area, lending
to the understanding of either the improvement/worsening of
symptoms or potential off-target side effects. Herein, we discuss
recent advances in the use of imaging technology for improving
DBS precision and outcomes.
Toward Precision Imaging and
Connectomic Surgery
Shortly after publishing their seminal paper about a stereotaxic
apparatus for human brain surgery in 1947 (Spiegel et al.,
1947). Ernest Spiegel and Henry Wycis published the concept
of ansotomy for treatment of Parkinsonian tremor (Spiegel and
Wycis, 1954) with the aim to cut pallidofugal efferent fibers
within the ansa lenticularis (Meyers, 1951). Hence, the concept
of retuning brain function by modulating brain connectivity is
actually a previously explored notion. What is new is our ability
to integrate electrode localizations with connectome data non-
invasively acquired using advanced MRI technology. Pioneered
by multiple groups worldwide (Coenen et al., 2009, 2011;
Anderson et al., 2011), this concept has become increasingly
powerful in order to understand how the effects of DBS
may impact the brain. When mapping DBS electrodes with
neuroimaging, it is crucial to attain the highest degree of accuracy
possible; since millimeters matter. Specialized neuroimaging
pipelines that have this goal in mind include multispectral
registration algorithms (Ewert et al., 2019), correction for
bias introduced by brain shift (Horn et al., 2019), phantom-
validated electrode reconstructions, and correction for detection
of directionality in the specific case of segmented leads (Dembek
et al., 2019). These tools allow us to precisely register DBS
stimulation sites to other datasets, such as histological atlases
(Ewert et al., 2018; Ilinsky et al., 2018), postmortem imaging
(Edlow et al., 2019), or to normative connectome data aggregated
from thousands of subjects (Horn et al., 2017a; Horn and
Fox, 2020). In cases where patient-specific connectivity data
is unavailable, normative connectome data can be an effective
surrogate (Baldermann et al., 2019; Wang et al., 2020) and can
potentially add the advantage of higher precision and increased
signal-to-noise ratios when including data from the postmortem
specimen (Calabrese et al., 2015), histology (Alho et al., 2020),
or with integrated anatomical expert knowledge (Petersen et al.,
2019; Middlebrooks et al., 2020; Figure 4).
A first report that applied this concept calculated a model of
optimal connectivity in a cohort of PD patients and used these
data to predict clinical improvement in a second cohort from
a different center (Horn et al., 2017b). Since this publication,
the concept has been applied to essential tremor, dystonia,
and epilepsy (Middlebrooks et al., 2018; Al-Fatly et al., 2019;
Okromelidze et al., 2020) and has been applied to predict
side-effects. Using a related technique termed tract-filtering,
specific bundles associated with optimal clinical improvement
can be identified. This technique was first used in an obsessive
compulsive disorder (OCD) cohort (Li et al., 2020).
In the future, a similar methodology could be used to define
symptom-specific circuitopathies that may ultimately facilitate
personalization of DBS targets to a somatotopic domain and
to a symptom-spectrum of individual patients. Furthermore,
advanced imaging technology will likely continue to enter the
operation room in an effort to integrate surgical targets with a
variety of neuroimaging data.
Utilizing Multi-Country Imaging and
Clinical Outcomes for Neuromodulation
Tourette syndrome (TS) is a complex neuropsychiatric disorder
characterized by tics and often associated with psychiatric
comorbidities, such as obsessive-compulsive behavior (OCB).
DBS is an effective therapy for select patients with severe,
treatment-refractory TS. However, patient responses to DBS
are variable and there are currently no reliable predictors of
symptom improvement. One contributing factor to the variability
in clinical outcomes is the uncertainty into how to optimally
target stimulation to improve tics or OCB. Progress toward
identifying predictors of symptom improvement and effective
neuroanatomical structures for stimulation has been limited by
the relative paucity of TS cases implanted at individual centers.
The International TS DBS Registry and Database (Deeb et al.,
2016) was established to overcome this limitation by aggregating
data from multiple international centers, including clinical data,
stimulation settings, clinical rating scale scores, and pre- and
postoperative imaging.
Using multicenter data from the registry, recent studies have
aimed to identify the neuroanatomical structures associated with
improvement in tics and comorbid OCB in patients who have
undergone DBS for TS. Image-based computational models were
constructed based on patient-specific lead locations and on
individual stimulation settings to visualize the active contact
locations across patients and to identify the structural networks
and local fiber pathways modulated by DBS (Figure 5). The
results highlighted the variability in applied stimulation across
patients (Johnson et al., 2019). Structural connectivity of the
site of stimulation and activation of specific local fiber pathways
were predictive of improvement in tics and comorbid OCB
(Johnson et al., 2020). The results could possibly be used
to refine stimulation targets and to develop network-based
approaches for DBS for TS in order to improve patient outcomes.
Collectively, these analyses demonstrate the value of combining
data across clinical centers in an effort to investigate DBS for less
common indications.
Predicting DBS Outcomes
Deep brain stimulation is an effective treatment for PD, but
its efficacy depends heavily on selection of optimal stimulation
parameters for each individual patient. DBS programming
is frequently time consuming and burdensome for patients,
caregivers, and clinicians. We recently conducted a multi-center
study (NCT02474459) to test if the integration of the Mobile
Application for PD DBS (MAP DBS), a clinical decision support
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FIGURE 4 | Using connectomics to guide surgery and DBS programming. (Top) DBS tract filtering. Four DBS electrodes implanted to the anteromedial subthalamic
nucleus and anterior limb of the internal capsule in a patient with obsessive compulsive disorder. Active contacts are marked in red. A tract associated with optimal
clinical improvement across 50 patients (limbic hyperdirect pathway within the anterior limb of the internal capsule) is shown in red, one associated with poor
improvement (posterior limb of the anterior commissure) in blue. (Bottom left) Clinical DBS setting. (Bottom middle) Upon further confirmation of results, based on
the existing electrode and the connectomic information, the stimulation settings could be optimized. (Bottom right) In novel patients, both surgical targeting and
DBS programming could potentially be optimized. Data from Li et al. (2020), background slices show the BigBrain dataset (Amunts et al., 2013) after precise
co-registration.
system, into the DBS programming process could transform
the care model by enabling home health nurses to effectively
manage patients at home. We conducted two open-label, 1:1
randomized, controlled, clinical trials. The first trial, which was
conducted at six expert DBS centers across the United States,
compared 6 months of SOC to 6 months of MAP DBS-aided
programming. The primary outcome was the total time spent on
DBS programming over all clinical visits during the study period.
In the second trial, we compared 6 months of SOC to 6 months of
home health postoperative DBS management. The home health
postoperative management was conducted by a home health
nurse who chose DBS settings with the aid of the MAP DBS
system. By design, the home health nurse had no prior experience
providing DBS care. The primary outcome was the number of
times each patient traveled to the movement disorders clinic
during the study period. In both studies, the secondary outcomes
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FIGURE 5 | Image-based analyses of multicenter data from the International Tourette Syndrome (TS) Deep Brain Stimulation (DBS) Registry and Database.
(A) Active contact locations for N = 70 patients implanted in the centromedial (CM) thalamus (red); anteromedial globus pallidus internus (GPi) (yellow); posteroventral
GPi (green); nucleus accumbens/anterior limb of internal capsule (NA/ALIC) (turquoise); CM thalamus and GPi (blue); or CM thalamus and NA/ALIC (purple). From
Johnson et al. (2019). (B,C) Stimulation-dependent structural connectivity associated with improvement in tics in patients implanted with DBS in the (B) GPi or
(C) CM thalamus. From Johnson et al. (2020).
were changes in the Unified Parkinson’s Disease Rating Scale
(UPDRS) part III (motor score), the total UPDRS (sum of parts
I through IV), the 39-question Parkinson’s disease rating scale
(PDQ-39), the Multidimensional Caregiver Strain Index (MCSI),
and levodopa equivalent daily doses (LEDD) between the baseline
and six-month outcomes visit. We analyzed 72 (SOC = 37, MAP
DBS = 35) patients in the first trial (Phase I). In the second
trial (Phase II: home health nurse management) we analyzed 42
patients (SOC = 19, home health = 23). The study results are in
submission but will help us to understand how tools like MAP
DBS can be used to enhance the experience of non-expert home
health nurses. Additionally, this data will be used to design and
pilot a study of home health nurse driven telemedicine in DBS.
CHRONIC BRAIN SENSING AND
ADAPTIVE DBS
Seminal papers on adaptive neuromodulation and brain
sensing have been primarily demonstrated in clinic or in
postoperative settings (Pina-Fuentes et al., 2017). While the
next generation device (i.e., Medtronic’s Summit RC + S) is
being released, which includes chronic neural sensing, long-
term home behavioral measurements may now be performed.
These findings validate what has been reported in short
perioperative settings, such as beta power alterations during
DBS. Additionally, chronic sensing allows us to continually
analyze pathological biomarkers, both subcortically and
cortically, or brain states and how they respond to stimulation,
aiding in the design of adaptive deep brain stimulation (aDBS)
paradigms. Furthermore, as aDBS expands into real-world
scenarios, the importance of defining individual biomarkers
and the optimal site for sensing develops along with the utility
of stereoelectroencephalography (sEEG) recordings before
implantation of the DBS lead placement (Sanger et al., 2018;
Shirvalkar et al., 2018). aDBS demonstrates promise in treating
complex dynamics in signals (such as beta bursts) (Tinkhauser
et al., 2017a,b; Deffains et al., 2018) or in disease states (such as
pain or epilepsy).
However, if we want to achieve optimal aDBS outcomes, not
only will electrode location and biomarker sensing be key, but
also, the type of control algorithm used will ultimately affect the
outcome and success of any aDBS paradigm. Previous control
algorithms for PD have used a pre-specified threshold on beta
(Little et al., 2013; Pina-Fuentes et al., 2017; Arlotti et al., 2018)
or gamma (Swann et al., 2018) power, voltage linearly following
beta power (Rosa et al., 2015), or dual threshold designs also
on beta power (Velisar et al., 2019; Petrucci et al., 2020). Newer
designs have focused on temporal dynamics of beta (Tinkhauser
et al., 2017a). How complex must aDBS algorithms be to capture
the dynamics of pathological biomarkers, especially as other
indications arise like chronic pain? Overall, preliminary studies
with chronic brain sensing will likely lead the way to a better
understanding of neural circuitry under various medication
and stimulation states and lead to the development of more
sophisticated methods for targeting, individual neural biomarker
or symptom identification profiles, and aDBS protocols across
neurological disorders.
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Chronic Sensing and Closed-Loop
Approaches in Parkinson’s
Invasive neural recordings in humans have shown promise
for understanding physiological signatures or “biomarkers” of
specific motor and non-motor signs of PD. Until recently,
most recordings were performed for short durations from
externalized brain leads in hospital settings. The availability of
bidirectional (sense and stimulate) neural interfaces has launched
a new approach: chronic invasive brain sensing at home.
This approach offers many advantages over brief recordings:
validation in the “real world” of biomarkers identified at rest with
externalized leads in defined medication states, identification
of “personalized” biomarkers based on chronic recordings over
many exacerbations and remissions of a specific sign or symptom
within a single subject, understanding effects of chronic DBS on
neural circuits, and implementation of aDBS. Here, we highlight
several uses of chronic brain recordings in PD at UCSF. Using an
investigational first-generation bidirectional interface, the Activa
PC + S (Medtronic) in four patients, we identified prefrontal
cortical beta band activity as a possible signature of anxiety and
depression. More recently we have used a second-generation
bidirectional interface, Summit RC+ S (Medtronic). This device
has the capability for high volume wireless data streaming at
home over many hours, improved signal to noise ratios, and
better management of stimulation artifacts as compared to its
precursor device. Five PD patients streamed bilateral 4-channel
motor cortex and basal ganglia field potentials at home for over
2,600 h. Recordings were paired with wearable monitors for the
neural decoding of motor fluctuations at home (Figure 6). We
validated personalized neural biomarkers during normal daily
activities. We examined the effects of chronic DBS and of sleep
on these biomarkers and implemented aDBS at home, using both
cortical and subthalamic signals to track motor fluctuations.
Closed-Loop Modulation and Brain State
Tracking for Epilepsy
Electrical brain stimulation (EBS) is an effective therapy
for neurological and psychiatric diseases. Currently available
systems, however, do not provide a bi-directional interface
suitable for ambulatory biomarker tracking, patient reporting, or
adaptive therapy. While regulatory challenges exist, integrating
EBS implants with off-the-body computing devices, like a
smart phone, can enable tracking, analyzing, and modulating
brain activity in ambulatory subjects while also providing
real-time behavioral data via phones and wearable sensors.
The bi-directional interface between ambulatory patients,
their brain activity, as well as the local and distributed
computing environments creates a powerful platform for therapy
optimization and neuroscience discovery.
Current FDA approved EBS devices for epilepsy do not
utilize adaptive therapy, take years for therapy optimization,
and do not track seizures or treat common comorbidities like
mood, sleep, and cognition. Here, we describe a Digital Epilepsy
Management System for drug resistant epilepsy that integrates a
brain stimulation and sensing implant with off-the-body devices
and cloud computing enabled ambulatory tracking of seizures,
biomarkers, behavior, sleep, cognition, and mood that can all
possibly drive adaptive therapy (Figure 7).
Pre-clinical work at the Mayo Clinic was completed in
research and pet canines with epilepsy using an investigational
Medtronic Summit RC + S (bilateral hippocampus and anterior
nucleus of the thalamus) sensing and stimulation implantable
device integrated with a tablet computer and cloud-based system
for streaming data acquisition from the brain and wearable
sensors, patient and device triggered tablet annotations, data
analytics, and visualization.
The system is currently deployed in a person with epilepsy
and 2 pet dogs with epilepsy living with their owners. We have
demonstrated automated seizure catalogs, interictal biomarker
tracking, sleep staging, and patient mood and cognition testing
in the naturalistic settings. The Digital Epilepsy Management
System provides an interactive interface between patient and
physicians and should be useful for optimizing adaptive EBS
therapy in patients with epilepsy.
Closed-Loop DBS for Refractory Chronic
Pain
A diverse array of chronic pain syndromes is refractory to almost
all treatment modalities; however, they involve pathological
activity in similar brain regions. This finding suggests therapeutic
potential for DBS to treat pain, but despite early promise,
long-term efficacy is lacking. Prior DBS approaches have been
limited in anatomical reach, targeting brain regions underlying
only single dimensions of pain (such as somatosensation).
Further, DBS therapy has been bluntly applied in an open-loop,
continuous fashion without regard to underlying physiology.
As a result of these shortcomings, DBS for pain is frequently
ineffective or shows diminished effect over time. DBS could be
significantly improved by seeking individually optimized brain
targets or by using neural biomarkers of pain to selectively
control stimulation when it is needed (closed-loop DBS). This
type of approach may help avert tolerance and may provide
prolonged pain relief.
Using personalized neural signatures of acute and chronic
pain states over long-time scales (weeks to months), we at
UCSF are developing a closed-loop DBS technology to treat
chronic pain. In our first cohort of four subjects with chronic
pain, we have implanted electrodes in the anterior cingulate
and orbitofrontal cortices. Using machine learning methods,
we have successfully decoded high versus low pain states and
identified personalized biomarkers of clinically relevant chronic
pain states. The stimulation of anterior cingulate cortex (ACC)
and orbital frontal cortex (OFC) has been variably analgesic with
inconsistent results over time. In a newer study, we are using
sEEG to perform a temporary stimulation trial of multiple brain
targets that underlie the somatosensory, affective, and cognitive
dimensions of pain. Based on this trial period, we can identify
personalized brain targets for each subject to maximize both
stimulation-induced pain relief and pain biomarker detection.
These pain biomarkers can then be used as a next step and be
embedded into closed-loop DBS control algorithms to provide
long term pain relief.
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FIGURE 6 | UCSF protocol for data streaming from Summit RC + S. Quadripolar leads were placed bilaterally into the subthalamic nuclei and over the motor cortex.
Leads were connected to the ipsilateral Summit RC + S neural interfaces. Each RC + S device wirelessly communicates with a pocket-sized relay device, usually
worn on the patient. The relay devices transmit by Bluetooth to a single small Windows-based tablet at a distance of up to 12 m, allowing sensing of local field
potentials from up to four bipolar electrode pairs for up to 30 h per device, before recharge is needed. Data from a wristwatch-style actigraphy monitor (Parkinson’s
Kinetograph, Global Kinetics) are synchronized off-line with neural recordings to facilitate brain-behavior correlations.
IMPULSIVITY AND NEUROPSYCHIATRIC
ASPECTS OF DBS
As DBS has proven successful in well-selected patients for the
treatment of movement disorders, such as PD and essential
tremor, its indications are expanding to include intractable
or severe neuropsychiatric conditions such as post-traumatic
stress disorder (PTSD; Larkin et al., 2020), OCD (Goodman
et al., 2020), and impulsive behavior (Wu et al., 2020).
As DBS expands into neuropsychiatry, several questions and
opportunities for development arise. These include optimal
targets or targeting, either anatomical or functional-based,
individualistic biomarkers of pathology, which can aid in the
development of aDBS paradigms, identifying circuitries involved
in psychiatric disorders, patient selection and ideal stimulation
paradigms (i.e., open- vs. closed-loop strategy).
Intracranial Neurophysiological
Biomarkers of Hypervigilance and Fear
in Humans
The ability to detect and subsequently remember threats is critical
for survival. However, extreme, or life-threatening situations,
can produce long-standing changes in fear-processing circuitry
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FIGURE 7 | Digital Platform for Neurological and Psychiatric Disease. Integration of brain implants, smart phones, wearable sensors, and computing environments
that provide data analytics synchronized with biomarker or user triggered interactions that can enable new therapy paradigms.
and these can lead to anxiety disorders such as PTSD. Through
a collaboration between Jean-Philippe Langevin, members
of the Suthana laboratory, and colleagues at the Veteran’s
Administration Greater Los Angeles Healthcare System, we
were able to record intracranial electroencephalographic (iEEG)
activity in veteran participants with implanted electrodes
placed within amygdala, hippocampal, and prefrontal regions.
Participants included those with an implanted RNS R© System
(NeuroPace, Inc.), sEEG electrodes for seizure evaluation, or
intra-operative recording electrodes implanted prior to DBS
placement in a patient with PTSD. A subset of the participants
was diagnosed with PTSD and/or generalized anxiety disorder
(GAD). Results yielded low and high frequency oscillatory
biomarkers that were and will be used to trigger responsive
neurostimulation in PTSD patients as part of an ongoing
NIH UH3 funded clinical trial. Future studies will focus
on characterizing amygdala-hippocampal-prefrontal circuit
mechanisms underlying fear-related memory and improve the
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ecological validity of laboratory-based tasks using virtual reality,
simultaneous physiological (e.g., heart rate, skin conductance,
and pupillometry) and iEEG activity combined with intracranial
electrical stimulation [for methods see (Topalovic et al., 2020)].
Development of Adaptive DBS for OCD
Ventral striatum (VS) DBS for treatment of intractable OCD
benefits approximately 50–60% of cases, leaving room for
improvement in both clinical outcomes and reduction of DBS-
induced behavioral side effects, notably hypomania. An adaptive
DBS (aDBS) system may improve efficacy of DBS for OCD by
facilitating the titration of stimulation parameters in response
to neural biomarkers of hypomania and in response to OCD-
related distress. In an NIH UH3 (NS100549; PI Goodman)
for aDBS in OCD, five participants underwent DBS surgery;
two with the Medtronic Activa PC + S, and three with the
Medtronic Summit RC + S. Participants returned to clinic
for DBS programming and to conduct neural recordings [local
field potentials (LFPs) and scalp EEG], video and heart rate
monitoring, as well as behavioral tasks, all measured on a bi-
weekly to monthly basis. Early evidence from one participant
suggested an increase in the left vs delta-band power over a
timeline of weeks since the DBS ON condition. This increase in
power preceded symptom improvement, which occurred after
an increase in pulse width from 90 to 120 µs that elicited
a mirthful response. In addition to in-clinic data collection,
we captured data in the participants’ home environments. The
Summit RC + S device enabled streaming of neural data at
home during natural fluctuations in OCD symptom intensity and
hypomania, as well as during exposure response therapy. There
were 228 h of neural data streamed from one Summit RC + S
participant during a range of behavioral states and tasks. The
majority of LFP data was collected during active DBS therapy.
To better understand underlying neural activity, we developed
a novel stimulation artifact removal paradigm, termed Period-
based Artifact Reconstruction and Removal Method (PARRM).
PARRM is applicable to various neurostimulation paradigms
beyond DBS, is superior in signal recovery, low complexity, and
requires minimal onboard storage. Next, we plan to examine
behavioral and neural data collected across various behavioral
states to identify biomarkers that can be deployed in an effort to
enable aDBS for OCD.
Closing the Loop on Impulsivity With
Deep Responsive Neurostimulation:
Past, Present, and Future of BITES
Loss of control (LOC) is a pervasive feature of eating disorders
and contributes significantly to the epidemic of obesity.
Responsive DBS that is guided by low-frequency changes in
the nucleus accumbens (NAc), was previously observed to
block binge-eating behavior in mice (Halpern et al., 2013).
Following novel preclinical work and a human case study which
demonstrated an association between the delta-band (1–4 Hz)
and reward anticipation, an Investigational Device Exemption
for a first-in-human trial was approved by the US FDA (Brain
Intervention Therapy for Eating Suppression, the BITES study).
BITES is a single site (Stanford University), early feasibility trial
with a randomized, single-blinded, staggered-onset design. Six
participants will undergo bilateral DBS of the NAc for LOC eating
using the RNS R© System (NeuroPace, Inc.). Eligible participants
must have treatment-refractory obesity with a body mass index
(BMI) 40–60 kg/m2.
There are three participants currently enrolled.
Electrophysiological signals of LOC will be characterized in
humans using ambulatory recording capabilities and controlled,
in-clinic behavioral tasks. We have developed novel behavioral
tasks and we will utilize virtual reality and eye-tracking to capture
anticipatory signals for LOC eating during intraoperative testing
and in the laboratory. Using eye-tracking and remote telemetry
communication, we captured real-time electrophysiological
signals during naturalistic eating behaviors in the clinic. We
assess LOC eating in the clinic by introducing participants
to a validated multi-item buffet task where they are given a
standard breakfast and lunch (500 kcal/meal), and following a
brief LOC priming period with mood provocation, participants
are presented a buffet of preferred, high fat-caloric food
(∼5,000 kcal). Further, we utilize ambulatory data collection
via magnet swiping which is paired with ecological momentary
surveys, food diaries, and wearables to capture real-world LOC
cravings and eating episodes. Initial piloting of these tasks and
assessments were used for feasibility in the initial pilot study and
analysis for a LOC-responsive biomarker study. Collectively,
these preliminary results demonstrate the usefulness of long-
term, objective neural recordings in naturalistic environments
and the potential of individualized biomarkers of pathology or
symptoms for the potential successful employment of aDBS.
EMERGING TECHNIQUES FOR DBS
New techniques for the application of DBS have emerged with the
advent of imaging, which has resulted in a paradigm shift toward
targeted modulation of a particular network (Gonzalez-Escamilla
et al., 2019, 2020; Horn et al., 2019). Another emerging and as yet
unresolved area is how beta oscillatory activity in the basal ganglia
is affected by DBS and how this is associated with symptom
improvement (Lofredi et al., 2019; Petersson et al., 2020). Studies
demonstrating suppression of beta activity by DBS revealed that
this was associated with amelioration of symptoms, and also with
an attenuation of this effect after continuous stimulation (Chen Y.
et al., 2020). This section summarizes the latest information on
device technology, structural/functional aspects, and biomarkers
for improved DBS programming.
Update on Emerging Technologies and
Deep Brain Stimulation
Initially, DBS was thought to mimic the effect of lesioning
through neuromodulation of neuronal activity within the
area surrounding the stimulating electrode. However, current
physiological concepts imply, that DBS has multiple, time-
dependent effects on the cellular, local neuronal circuitry and also
at the large-scale network level. These changes may influence the
dysfunctional activity within symptom specific neural circuits.
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Axons originating or terminating within the stimulation volume
or bypassing it are the key elements potentially mediating
multiple clinical responses (Kuhn and Volkmann, 2017; Lozano
et al., 2019). Therefore, ideal neurostimulation technology.
• should be flexible in stimulating only a small volume of
interest,
• should preferentially stimulate axons mediating benefit,
• should avoid stimulation of axons or other excitable
elements resulting in adverse effects,
• should eliminate the neuronal signal mediating a network
dysfunction (e.g., oscillopathy),
• should not interfere with normal (physiological) network
function.
Recent methodological advances addressing these needs
include segmented electrode designs and an expanded
pulse parameter space (e.g., shorter pulse durations, anodic
stimulation) for more precise delineation of the stimulation
volume and for selective stimulation of particular fiber pathways
of interest. Another advance includes sensing capability
using either brain signals or peripheral kinematic sensors to
adapt stimulation to fluctuating symptom severity and to the
underlying dynamics of neural circuits. Finally, future advances
include the rapidly advancing field of digital innovations for
clinical response prediction which may inform and substantially
shorten programming times for DBS.
Several open source and commercial software have facilitated
visualization of the volume of tissue activated (VTA) based on
axon cable models in patient specific anatomical models (derived
from MRI and CT imaging). Aggregated data from large patient
cohorts have facilitated the creation of probabilistic maps of
clinical responses, which in turn can be used to train machine
learning algorithms for predicting a clinical (individual) response
with a given electrode location and a particular stimulation
setting (Reich et al., 2019). We hope, that resulting “expert
systems” will help to better manage DBS patients in a more
reliable and consistent way across centers and will reduce the
need for high-level individual expertise in DBS programming.
A clinical trial (site: University of Würzburg, Germany)
comparing machine based and best clinical programming in
dystonia has recently received funding from the German Ministry
of Research and Technology and will be initiated in 2021
(DIPS: Dystonia Image-based Programming of Stimulation: A
prospective, randomized, double-blind crossover trial).
Structural and Functional Network
Characterization for Prediction of DBS
Patients
Despite the vital role of brain network studies to predict disease
trajectories in patients with movement disorders, their analysis
and modeling are often difficult to interpret due to complexity,
uniqueness, test-retest issues and group or single subject validity
of the data. Of distinct importance for the comprehension of the
analytical framework is to note, that network interactions occur at
specific spatial locations within regions (space) over distinct time
dimensions (state). With this in mind, we hypothesize that brain
networks have instantaneous state and space properties at each
level. Proper identification and association of features (within and
between brain regions) from these critical variables at different
time scales can be modeled by newly proposed computational
approaches (Gonzalez-Escamilla et al., 2020; Muthuraman et al.,
2020) that can then have the potential to predict individual
responses to DBS.
In a recent review, we comprehensively describe the
causal interrogations and modulations of network states using
neuroimaging and electrophysiology (Gonzalez-Escamilla et al.,
2020). Using structural magnetic resonance imaging (sMRI),
we were further able to show in the pre-operative MRI the
cortical thickness (CT) in the frontal lobe predicted the clinical
improvement after STN-DBS (Muthuraman et al., 2017) and
cortical atrophy in sensorimotor areas in dystonia patients
(Gonzalez-Escamilla et al., 2019). In the same direction, frontal
lobe network proxies can predict postoperative clinical response
to STN-DBS using diffusion tensor imaging (DTI; Koirala et al.,
2018). By using functional state recordings and analyses from
electroencephalography (EEG) and electromyography (EMG)
we were able to show the topography of oscillatory coherent
sources in the cerebellum and sensory-motor cortex could
robustly separate patients with different tremor syndromes and
act as variables for closed-loop approaches (Muthuraman et al.,
2018). Moreover, in advanced network analyses using a similar
analytical framework with high-density EEG we described cross
frequency coupling as a marker for clinically effective DBS of
the STN-DBS, that modifies fine-tuned gamma oscillations for
the optimal clinical response (Muthuraman et al., 2020). After
identifying these network proxies (Figure 8), the aim is for rapid
translation of scientific knowledge to clinical practice. There is a
clear need for testing of this proposed state- and space framework
in the clinical setting.
Local Field Potentials as Biomarkers for
DBS Control and Programming
Over the last decade, we and others have used the access to deep
brain nuclei in patients undergoing DBS not only for treatment
of motor symptoms, but also to record neuronal activity in order
to understand the underlying pathophysiology of movement
disorders. We could show that the temporal pattern of neuronal
output is highly important to understanding network disorders.
The oscillatory activity pattern is different in bradykinetic and
hyperkinetic disorders, i.e., dynamic changes in the network
related to a specific motor state of the patient. Best known is the
increased subthalamic oscillatory beta (13–35 Hz) band activity
which has been shown to be a potential electrophysiological
signature of bradykinetic motor signs in patients with PD
(Silberstein et al., 2003). Dopaminergic medication has been
associated with a decrease of this pathologically enhanced
activity, specifically in the low beta sub-band (13–20 Hz) (Kuhn
et al., 2006, 2008).
In several studies, a significant correlation between
parkinsonian symptom severity and beta synchronization
has been reported (Kuhn et al., 2006, 2008), even months
after neurostimulator implantation (Neumann et al., 2017).
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FIGURE 8 | The methodological framework to entangle network proxies for prediction of the outcome of the DBS patients from volume of tissue activated (VTA)
modeling to identifying the correct modalities to identify the network changes and use it for individual prediction using matching learning algorithms.
Moreover, beta band activity has been shown to be suppressed
by neuromodulation (Kuhn et al., 2008; Eusebio et al., 2011).
Research has focused on the improvement of DBS and there
has been movement toward more patient-tailored, adaptive
stimulation (aDBS). The idea of aDBS has been to switch
stimulation ON/OFF or to modulate the stimulation amplitude
in response to the real-time analysis of a potential biomarker,
e.g., beta band activity in PD (Little et al., 2013). A recent
technical development has facilitated chronic sensing using
the PERCEPT (Medtronic) pulse generator. This new technical
advancement will help to define the biomarker as a feedback
signal for future adaptive DBS.
Our first experience with PERCEPT has revealed that a
stepwise increase of stimulation amplitude was mirrored in the
sequential decrease of beta oscillatory activity, which occurred
in parallel with the improvement in bradykinesia. Mean beta
band (13–20 Hz) activity correlated significantly with the UPDRS
scores during DBS. Further studies using chronic sensing will
likely reveal circadian fluctuations in oscillatory patterns. This
will also likely be useful for application to aDBS in real





This section describes the advances in the field of
neurotechnology as applicable to DBS research. This includes
real-time neural recordings, remote DBS programming,
optimization of electrode configurations, and model-based
algorithms, which can all be developed to further incorporate
physiological signals in the optimization process. Finally,
we address issues surrounding chronic implantation and
utilization of neural micro-devices, which have the potential
to provide sensory information feedback, and how to mitigate
these issues.
Real Time Recording of EEG and ECG
Using DBS Electrodes
With sensing-enabled deep brain stimulators, chronically
monitoring neural activities in the deep brain has become
a reality. This capability could play a key role in clinical
neuroscience and neuromodulation technology. We developed a
DBS system with the capability of chronic recording (Qian et al.,
2016). We investigated artifact removal methodologies (Qian
et al., 2017a,b) and we built a software platform to improve signal
recording and signal processing. Based on this technology, we
conducted longitudinal clinical recordings to observe chronic
LFPs and the effects of DBS on neuromodulation (Qian et al.,
2016). The results have revealed that there may be a chronic
change in the beta suppression of DBS in the subthalamic
nucleus of PD patients.
In addition to this change we also observed combinations of
alpha, beta and gamma bands which could be used as chronic
biomarkers for the classification of different sleep stages (Chen
et al., 2019). The results have guided the development of a
closed-loop DBS approach. Recently, this sensing-enabled device
has been improved by employing Bluetooth communication,
facilitating the potential for the application of implantable
brain-machine interfaces. The latest advance has been the first
Bluetooth DBS device which was implanted in China. The device
could directly connect to a mobile device by Bluetooth and was
capable of transmitting up to eight channels of LFPs, one channel
of ECG as well as 3-D acceleration signals (Figure 9).
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FIGURE 9 | Remote real-time deep brain recording and DBS tele-programming. (A) The G106RS system, a sensing-enabled DBS with Bluetooth connection, can
monitor deep brain rhythms remotely. Specifically, it was capable of transmitting up to eight channels of local field potentials (LFPs) with 1,000 Hz sampling rate, one
channel of electrocardiogram (ECG) and 3-D accelerometer signals; (B) DBS patient equipped with G106RS device with Bluetooth connection and wireless
charging. A tele-programming DBS system can remotely adjust parameters via Bluetooth technology by the provider. The LFP, ECG and 3-D accelerometer signals
can be transmitted remotely from the G106RS device to a data receiver accessed by the provider.
Remote DBS Programming During
COVID-19 Pandemic
In the past five years, remote programming technology has been
widely expanding in large medical centers specifically in an
effort to improve access, and particularly for those residing in
remote locations. At the beginning of the COVID-19 pandemic,
many patients were secluded from standard medical services due
to social distancing, quarantine, and lockdowns. For patients
with PD, efficient programming could be safely achieved by a
remote tele-programming system. We have developed a DBS
programming technology using a Bluetooth communication
interface. We reported the application of the device during the
pandemic, particularly for PD patients with freezing of gait
(FOG) who were able to be programmed with a complex variable
frequency stimulation (VFS; Jia et al., 2018) paradigm (Zhang
et al., 2020). This technology could potentially be shared among
multiple medical centers when paired with the implementation of
adequate privacy protections.
Our remote programming system provides a promising
approach for the control of a wide range of implantable
medical devices. We anticipate that telemedicine for
remote DBS programming will be an important trend in
future DBS management.
Model-Based Algorithms for Optimizing
DBS Therapy
Computational models of DBS have provided significant insight
into the regions and pathways involved in treatment and
side effect induction with DBS therapy. To date much of the
research has focused on retrospective analysis in which previously
collected clinical outcomes are matched with model predictions
of the regions or pathways activated by clinically optimized or
suboptimal stimulation settings that may or may not induce side
effects. As we continue to pursue these retrospective studies, the
knowledge gained provides an opportunity to build data-driven
algorithms for identifying therapeutic electrode configurations
prospectively and on an individual subject basis.
Several targeting algorithms have been developed in recent
years including neural network classification based on VTA
morphologies (Chaturvedi et al., 2013), convex optimization for
targeting several (Xiao et al., 2016), or a broader range (Anderson
et al., 2018) of axonal pathways, orientation-selective stimulation
(Lehto et al., 2017; Slopsema et al., 2018, 2020) and particle
swarm optimization that can incorporate single (Pena et al.,
2017) or multiple (Pena et al., 2018) objective functions. While
these studies have focused primarily on optimizing electrode
configurations, including monopolar and multipolar stimulation,
and stimulation amplitude, model-based algorithms have also
shown utility for optimizing the pattern of stimulation (Brocker
et al., 2017; Cassar et al., 2017) and the shape and size of DBS
(Howell et al., 2015) electrodes (Teplitzky et al., 2016).
Model-based algorithms can also be extended to incorporate
physiological signals in the optimization process. Examples of
these approaches include adaptive closed-loop strategies that
integrate a response surface model to intelligently guide and
update stimulation parameters. One recent example is the
development of Bayesian adaptive dual control that balances
exploitation of DBS settings that are known to be therapeutic
with the exploration of settings that may yield a better outcome
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(Grado et al., 2018; Figure 10). As telehealth becomes more
mainstream for DBS programming and in cases in which the
clinical effects of DBS have long wash-in and wash-out time
constants, model-based optimization algorithms are poised to
make a significant future impact.
Engineering the Neuronal Response to
Electrical Microstimulation
The loss of sensorimotor function has devastating consequences
on quality of life. One approach to restoring lost sensorimotor
abilities is to supply patients with implants that provide a direct
interface with the central nervous system. For an amputee
or tetraplegic patient, this interfacing could allow a patient’s
desired limb movement to be executed by a prosthetic limb,
and to convey to the patient, sensory information about the
consequences of these movements. Highly sophisticated robotic
limbs have been developed, as have algorithms to decode
motor commands from the brain. However, somatosensory
feedback is critically important in activities of daily living.
Furthermore, touch is important in emotional communication
and in embodiment of our limbs. Without touch, the dexterity
of the prostheses will be limited, as will the degree to
which they are incorporated into the self-image. Given the
importance of touch, upper limb neuroprostheses may not
be clinically viable until these devices provide informative
tactile feedback.
Direct interfacing of micro-devices with the brain has the
potential to provide sensory information feedback. However,
chronic implantation and utilization of neural micro-devices
can result in a reactive tissue response that both functionally
isolates the device from the tissue as well as triggers neuronal
apoptosis or migration. The goal of our research is to
understand and to mitigate this limited functionality. Our
research seeks to determine the interdependent effects of device
design, electrophysiological recording, electrical stimulation,
and the reactive tissue response on the efficacy of neural
interfaces. We: (1) conduct psychophysical experiments using
multi-channel cortical implants in the cortex, (2) collect
longitudinal electrochemical and electrophysiological recordings,
(3) investigate mitigation strategies, and (4) use advanced
histological approaches to evaluate the device-tissue interface.
Our lab studies these various approaches and their implications
for reliable chronic neural interfacing via micro-devices. We
expect that these data will enable further neuroprosthetic
development for many neural interfaces’ potential applications.
FIGURE 10 | Multi-objective particle swarm optimization algorithm for determining DBS parameter sets that more selectively active one or more axonal pathways
adjacent to a DBS lead. (A) Multiple particles explore electrode configurations and stimulation amplitudes, and are guided by panel (B), an inertial, cognitive, and
social component amongst the N particles. (C–E) Particles are mapped onto a multi-objective space that describes the goal of activating one or more pathways over
other pathways within the brain. Through an iterative process, non-dominated particles are tracked to create a Pareto front with particles corresponding to optimized
electrode configurations. Reproduced with permission from Pena et al. (2018).
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SUMMARY AND CONCLUSION
The Eighth Annual DBS Think Tank meeting provided scientific
insight into the most current commercially available technologies
and also facilitated important dialogue as to how clinical
outcomes may be influenced The topics included (1) closed-
loop and adaptive DBS for the treatment of multiple emerging
indications, (2) improved imaging techniques which could
expand our understanding of brain circuitry and improve
DBS outcomes by offering more personalized targeting, (3)
optogenetics to elucidate the fundamental roles of various
cell types in the neurobiology of disease and could lead to
a better understanding of pathological brain circuitries, and
(4) the use of chronic neural recordings to define symptom-
specific, individualized biomarkers. The Think Tank also
addressed a multitude of emerging ethical issues arising from
research and from the application of these aforementioned
technologies, especially when DBS is successfully applied for off-
label uses. We discussed the ethical implications of post-trial
management. Furthermore, attendees of the DBS Think Tank
completed a questionnaire and 178 participants responded. The
participants were primarily scientists or clinicians at academic
institutions/universities. The weighted-mean experience in the
field of neurotechnology of the participants was 12.3 years.
Within the last year, DBS for essential tremor and PD remain
at the slope of enlightenment, with mean scores of 5.38 and
5.36, respectively. Additionally, cochlear implants have joined
the slope of enlightenment this year. Optogenetics for clinical
neural interfaces remains as a technology trigger. Several DBS
indications (PTSD, obesity, traumatic brain injury, addition,
Alzheimer’s) have moved from technology trigger to peak of
inflated expectations, corresponding to the expanding research
and clinical trials. Results indicated that some uses and
techniques of DBS remained on the trough of disillusionment
(intraoperative physiology, imaging post DBS implant, DBS
for epilepsy, DBS for Tourette) or moved to the trough
of disillusionment (DBS for OCD, DBS for chronic pain,
closed-loop DBS).
These proceedings present the latest advances in the field
of neuromodulation and emerging challenges that will require
international collaboration to more rapidly advance DBS therapy.
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